After its first phase 3 trial of obesity hope CagriSema left investors dissatisfied, Novo Nordisk has a plan to get the programme back on track. Pfizer has paid $60m to settle US government ...
Pharmaceutical companies are eagerly pursuing GenAI products and use cases to generate value within their organisations. Many are heavily investing in consultants to help develop strategies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback